A 24-week Two-armed Proof-of-concept Exploratory Analysis of Subcutaneous Ixekizumab Administration in Patients With Recalcitrant Non-infectious Intermediate, Posterior, Panuveitis, or Chronic Steroid-dependent Anterior Uveitis.
Latest Information Update: 19 Oct 2023
At a glance
- Drugs Ixekizumab (Primary)
- Indications Anterior uveitis; Intermediate uveitis; Panuveitis; Posterior uveitis
- Focus Therapeutic Use
Most Recent Events
- 19 Oct 2023 New trial record